Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis
- PDF / 8,567,216 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 172 Views
Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR‑429/TFAP2A axis Huiying Xu1 · Lingyan Wang2 · Xiuli Jiang3 Received: 8 July 2020 / Accepted: 31 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Long non-coding RNAs (lncRNAs) are known as crucial regulators in the development of OC. In the current study, we aim to explore the function and molecular mechanism of lncRNA DLEU1 in OC. Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to determine the expression of DLEU1, miR-429, and TFAP2A in OC cells and tissues. The relationship among DLEU1, miR-429, and TFAP2A was tested by dual-luciferase reporter (DLR) assay. Besides, the proliferative, migratory and invasive abilities of OC cells were analyzed by MTT, wound healing, and transwell assays, respectively. Western blot was performed to determine the protein expression of TFAP2A. The expression of lncRNA DLEU1 and TFAP2A were upregulated, and miR-429 was downregulated in OC tissues. Silencing of DLEU1 inhibited the proliferation, migration, and invasion of OC cells. Bioinformation and DLR assay showed that DLEU1 acted as the sponge for miR-429. Moreover, miR-429 could directly target TFAP2A and inhibit the proliferation, migration, and invasion of OC cells. Moreover, we observed a negative correlation between miR-429 and DLEU1, and between miR-429 and TFAP2A in OC tissues. The transfection of miR-429 inhibitor or pcDNA-TFAP2A reversed the inhibitory effects of si-DLEU1 on the proliferation, migration, and invasion of OC cells. Silencing of DLEU1 inhibited the proliferation, migration, and invasion of OC cells by regulating miR-429/TFAP2A axis, indicating a potential therapeutic target for OC. Keywords Ovarian cancer · Long non-coding RNA DLEU1 · MicroRNAs · miR-429 · TFAP2A
Introduction Ovarian cancer (OC) is the most mortal gynecological cancer, accounting for 5% of female cancer deaths worldwide [1]. Over 70% of patients are diagnosed with advanced tumor and a five-year survival rate for patients with advanced tumor is about 20–30% [2]. This poor outcome is mainly caused by late diagnosis and chemotherapy resistance [3]. Although surgery and chemotherapy have been * Xiuli Jiang [email protected] 1
Department of Gynaecology and Obstetrics, The First People’s Hospital of Lanzhou City, No. 1, Wujiayuan West Street. Qilihe District, Lanzhou, Gansu 730050, China
2
Department of Gynecology, Binzhou Chinese Medicine Hospital, Bincheng District, No. 539, Bohai 8th Road, Binzhou, Shandong 256600, China
3
Department of Gynecology, People’s Hospital of Yucheng City, No. 753, Kaituo Road, Yucheng City, Shandong 251200, China
widely used in the treatment of OC, the prognosis of OC patients remains unsatisfied. Therefore, to accomplish better clinical outcomes, it is urgently needed to explore the molecular mechanisms of OC and identify new therapeutic targets. Many molecular mechanisms have been verified to exert vital roles in regulating the pathogenesis, me
Data Loading...
